Longeveron (LGVN) Capital Expenditures (QoQ) (2020 - 2025)
Longeveron (LGVN) Capital Expenditures (QoQ) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn |
| 10 | Longeveron | 15.12 Bn | 15.10 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -64.60% |
| Jun 30, 2025 | 496.30% |
| Mar 31, 2025 | 107.69% |
| Dec 31, 2024 | -96.98% |
| Sep 30, 2024 | 119.39% |
| Jun 30, 2024 | 1,125.00% |
| Mar 31, 2024 | -90.24% |
| Dec 31, 2023 | 5,366.67% |
| Sep 30, 2023 | -96.74% |
| Jun 30, 2023 | 119.05% |
| Mar 31, 2023 | -36.36% |
| Dec 31, 2022 | -82.54% |
| Sep 30, 2022 | 384.62% |
| Jun 30, 2022 | 65.96% |
| Mar 31, 2022 | -84.94% |
| Dec 31, 2020 | -200.00% |
| Sep 30, 2020 | 1,200.00% |
| Jun 30, 2020 | -99.23% |